An observational study in Ureteral Stricture, Ureteral Obstruction and Microbiome, sponsored by First Affiliated Hospital of Chongqing Medical University. Not yet recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-02-13.
Sponsored by First Affiliated Hospital of Chongqing Medical University · Observational
The goal of this observational study is to investigate the systemic pathogenesis and identify potential diagnostic biomarkers in patients with ureteral stricture and healthy volunteers. The main questions it aims to answer are:
What are the systemic differences in the gut microbiome, urine microbiome, and metabolomic profiles (fecal, urinary, and serum) between patients with ureteral stricture and healthy controls? What are the correlations between these microbial/metabolic alterations and clinical phenotypes, such as stricture severity, inflammatory levels, and renal function? Researchers will compare the biological panoramic profiles of patients with ureteral stricture to those of healthy controls to see if specific "microbiome-metabolite-disease" regulatory networks drive the development of the condition.
Participants will:
Provide stool samples for gut microbiome (16S/Metagenomics) and metabolomic analysis.
Provide urine samples for urine microbiome and metabolomic analysis. Provide blood (serum) samples for systemic metabolomic profiling. Undergo clinical assessments, including medical history collection, imaging (e.g., CT/IVP), and laboratory tests (e.g., renal function, inflammatory markers) to evaluate disease severity.
Background and Scientific Rationale Ureteral stricture is a major urological challenge that leads to urinary tract obstruction and progressive renal impairment. While its etiology is diverse-ranging from iatrogenic injury to congenital anomalies-the underlying molecular mechanisms, particularly in inflammatory and idiopathic cases, remain poorly understood. Current surgical interventions carry a risk of recurrence, underscoring the urgent need to identify systemic biomarkers and novel therapeutic targets.
The Gut-Kidney Axis and Urinary Microbiome Recent advances have highlighted the "gut-kidney axis," where the gut microbiota and its metabolites modulate distant organ pathology through immune regulation and metabolic signaling. Furthermore, the discovery of a unique urinary microbiome has challenged the traditional view of urinary sterility, suggesting that local dysbiosis may contribute to urological diseases. Metabolites, serving as the functional intermediaries between the microbiome and the host phenotype, provide a critical bridge to understanding these complex interactions.
Integrated Multi-omics Strategy
This study adopts an innovative integrated multi-omics approach to characterize the biological landscape of ureteral stricture across three compartments: the intestine, the urinary tract, and the systemic circulation. By combining high-throughput sequencing of gut and urine microbiomes with mass spectrometry-based metabolomic profiling (fecal, urinary, and serum), we aim to:
Map Systemic Dysbiosis: Identify specific microbial taxa and metabolic signatures that distinguish patients with ureteral stricture from healthy individuals.
Elucidate Regulatory Networks: Construct "microbiome-metabolite-disease" networks to explore how microbial alterations correlate with clinical phenotypes, such as fibrosis markers, inflammatory levels, and renal function indicators.
Identify Functional Pathways: Utilize functional enrichment analysis to pinpoint metabolic pathways (e.g., those related to inflammation or tissue fibrosis) that are modulated by the microbiota.
Clinical Significance The ultimate goal of this research is to provide a systemic biological perspective on the pathogenesis of ureteral stricture. By integrating cross-platform data, we expect to identify high-sensitivity non-invasive biomarkers for early diagnosis and provide a theoretical foundation for future microecology-targeted interventions.
The study population consists of adult patients diagnosed with ureteral stricture who are seeking medical consultation or surgical treatment at the Department of Urology in a tertiary medical center The First Affiliated Hospital of Chongqing Medical University. These patients represent a diverse range of etiologies, including iatrogenic, inflammatory, and idiopathic narrowing.
Simultaneously, a cohort of healthy volunteers will be recruited from the hospital's physical examination center or the local community to serve as the control group. These volunteers are age- and sex-matched to the patient group and share a similar geographic and dietary background to minimize environmental confounding factors in microbiome and metabolomic analysis.
Inclusion Criteria (Ureteral Stricture Group):
Age between 18 and 75 years, regardless of gender. Diagnosis of ureteral stricture confirmed by clinical symptoms and imaging (e.g., CT, IVP, or retrograde pyelography) or ureteroscopy.
The patient is scheduled for or undergoing standard clinical evaluation/treatment for ureteral stricture.
Willingness to provide stool, urine, and blood samples. Informed consent signed by the participant or their legal representative.
Inclusion Criteria (Healthy Control Group):
Age- and sex-matched volunteers (18-75 years). No history of ureteral stricture, urinary tract obstruction, or significant renal disease.
Physical examination and laboratory tests (renal function, routine urine analysis) are within normal limits.
Exclusion Criteria (Applicable to Both Groups):
Use of antibiotics, probiotics, prebiotics, or antifungal medications within the 4 weeks prior to sample collection.
History of chronic gastrointestinal diseases (e.g., Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), or chronic diarrhea).
Known malignant tumors of the urinary tract or other systemic malignancies. History of major abdominal or urinary tract surgery within the last 3 months (excluding the current planned procedure for patients).
Presence of severe systemic diseases, including uncontrolled diabetes, severe hepatic dysfunction, or end-stage heart failure.
Pregnancy or breastfeeding. Any other condition that, in the opinion of the investigator, may interfere with the microbiome or metabolomic analysis.
Patients diagnosed with ureteral stricture through clinical symptoms, imaging (e.g., CT, IVP, or retrograde pyelography), or endoscopic evaluation. This cohort includes individuals with iatrogenic, inflammatory, or idiopathic strictures. Intervention of interest: Participants will undergo biological sample collection, including fecal samples for gut microbiome and metabolome analysis, mid-stream urine for urinary microbiome and metabolome analysis, and fasting blood samples for systemic serum metabolomic profiling. Clinical data such as renal function and stricture characteristics will also be recorded.
Age- and sex-matched healthy volunteers with no history of ureteral stricture, urinary tract obstruction, or significant renal diseases. Candidates with recent (within 3 months) use of antibiotics or probiotics, or those with chronic gastrointestinal or metabolic disorders, are excluded. Intervention of interest: This cohort will provide identical biological samples (fecal, urine, and blood) following the same protocols as the patient group to establish a baseline for comparative multi-omics analysis.
Differences in Gut and Urinary Microbiome Composition
Comparison of microbial diversity and taxonomic composition between ureteral stricture patients and healthy controls. Metrics include Alpha-diversity (e.g., Shannon Index), Beta-diversity (e.g., PCoA based on Bray-Curtis distance), and relative abundance of specific microbial taxa from Phylum to Genus levels using 16S rRNA or metagenomic sequencing.
Time frame: Baseline (at the time of sample collection, within 1 week of enrollment)
Differential Metabolomic Profiles in Fecal, Urinary, and Serum Samples
Identification of significantly different metabolites between the two groups. Parameters include the concentration and relative intensity of metabolites identified via LC-MS/MS or GC-MS. Significant metabolites will be screened based on Variable Importance in Projection (VIP) \> 1.0 and p-value \< 0.05 from multivariate and univariate statistical analyses.
Time frame: Baseline (at the time of sample collection, within 1 week of enrollment)
Plan to share: Undecided — The decision to share individual participant data (IPD) is currently under evaluation. The investigators will finalize the data sharing plan after reviewing the institutional data management policies and ensuring that all sharing protocols strictly adhere to participant privacy and ethical guidelines. A final determination will be made at the time of publication.
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
First Affiliated Hospital of Chongqing Medical University